Overdose clinical trials

Explore recruiting overdose clinical trials.

Recruiting overdose studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overdose trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Early optimization of ceftazidine dosing regimen in critical care : FORTOPTIM_1

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Benzodiazepine stabilizing treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR)

Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults with Opioid Use Disorder (Opioid Dependence)

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Spain, France, Italy, Belgium, Germany, Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)

Italy, Belgium, Spain, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Overdose trials by city

Overdose in Toronto Overdose in Vancouver Overdose in Montreal Overdose in Calgary Overdose in Edmonton Overdose in Ottawa Overdose in Winnipeg Overdose in Quebec City Overdose in Hamilton Overdose in Kitchener Overdose in London Overdose in Halifax Overdose in New York Overdose in Los Angeles Overdose in Chicago Overdose in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease